COLLABORATIVE SCIENTIST GETS GRANTResearch scientist Barbara Weiffenbach of CollaborativeResearch Inc. (NASDAQ:CRIC) of Bedford, Mass., has received a$175,000 grant from the Muscular Dystrophy Association to aidher search for the specific gene thought to causefacioscapulohumeral muscular dystrophy (FSH), a disease thataffects the muscles of the face and upper body.

The association last week awarded almost $6 million in grantsfrom a $23.5 million fund to 98 scientists in the United Statesand four foreign countries. The largest one-year grant,$207,191, was awarded to Dr. Kenneth H. Fischbeck of theUniversity of Pennsylvania School of Medicine's Department ofNeurology for his research in identifying the gene responsiblefor one form of Charcot-Marie-Tooth disease, a progressivedisease of the peripheral nerves involving weakness of thehands and lower legs.

MARROW-TECH GRANTS MARKETING RIGHTS

Marrow-Tech Inc. said Friday that it has entered intoagreements with two Asian companies to market its Skin2toxicology screening kits. Oriental Yeast Co. Ltd. of Tokyo willhave exclusive marketing rights in Japan, and PentachemEnterprise Co. Ltd. of Taipei will have exclusive Taiwaneserights. The agreements specify minimum purchases of about$300,000, with options for renewal after one year.

Skin2 kits consist of living human skin tissue grown usingMarrow-Tech's proprietary technology. Marrow-Tech(NASDAQ:MAROA), based in La Jolla, Calif., began marketingSkin2 in the United States last November.

QUANTUM TO MARKET UNISYN IN U.K.

UniSyn Fibertech Corp. of San Diego has signed an exclusivedistribution agreement with Quantum Biosystems Ltd. ofCambridge, United Kingdom, for marketing of all UniSynproducts and technology in the United Kingdom.

UniSyn, which is privately held, manufactures hollow fiber-based instrumentation and bioreactors for the manufacture ofmonoclonal antibodies, recombinant proteins, viruses and viralantigens.

(c) 1997 American Health Consultants. All rights reserved.